[{"orgOrder":0,"company":"University of California","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"University of California","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Polyhexanide","moa":"Cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VPO-227","moa":"CFTR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"6","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Avrobio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"UCLA \/ Trethera","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ Trethera"},{"orgOrder":0,"company":"University of California","sponsor":"Emalex Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Emalex Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||duoCAR T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"10","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Degarelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"University of California","sponsor":"Releviate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"RLVT-9-01","moa":"MMP-9","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Releviate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Releviate Therapeutics"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Thrixopelma Pruriens Venom Peptide","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ AmbioPharm"},{"orgOrder":0,"company":"UCLA","sponsor":"Medicinova","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"University of California","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ National Institute on Aging"},{"orgOrder":0,"company":"University of California","sponsor":"Myto Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Monomethyl Fumarate Prodrug","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"NemaLife","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Psychoplastogen","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"UCLA \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institutes of Health"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"University of California","sponsor":"Shuttle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ University of California"}]
Find Clinical Drug Pipeline Developments & Deals by University of California
Details :
Under the licensing agreement, Trethera will holds the exclusive rights for the clinical development of TRE-515, which is beingt evaluated for the treatment of neoplasms.
Details :
The collaboration aims to evaluate the Akantior (polihexanide), the first and only approved drug for the treatment of AK. It is being indicated for the treatment of Acanthamoeba Keratitis in US.
Details :
Under the agreement, the company aims to advance the preclinical development of Shuttle Diagnostics ligand for the PSMA as a potential diagnostic and therapeutic, or theranostic, molecule.
Details :
The proceeds will be used to prepare a potential disease-modifying Alzheimer’s treatment, CNDR-51997, which prevented tau from becoming detached from microtubules, for future clinical trials.
Details :
ARD-101 (denatonium acetate) is a first-in-class oral substantially gut-restricted with minimal systemic exposure yet conveys systemic effects via activation of GLP-1, GLP-2, and which show positive impact on hunger scores in general obesity and Prader-W...
Details :
MYT-109 improves mitochondrial functions and rescues lethality in animal models of Leigh’s Syndrome. It’s a prodrug, using a proprietary technology, with improved PK compared to other fumarate based drugs.
Details :
VPO-227 is a small-molecule with a novel mechanism of action which blocks the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel,in development for the treatment of secretory disorders, including cholera.
Details :
Initiation of the Phase 1/2a trial represents the first-in-human clinical study investigating a dual chimeric antigen receptor (duoCAR)-T cell therapy for the treatment of HIV.
Details :
TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.
Reset All
